NC525 (novel investigational agent for advanced myeloid neoplasms)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-01-28 — A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms: Phase 1 open-label, non-randomized first-in-human trial evaluating safety, tolerability, and efficacy of NC525 in subjects with advanced myeloid neoplasms (trial-early; no outcome data yet reported). (novelty: 3)
Open questions
Related
Contributing findings
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
28-jan-2026
novelty 3
per-area 3
introduces